相关实验视频

Updated: Jul 6, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

对于非酒精性脂肪肝疾病的潜在治疗点:类似葡萄糖的1

Yue-Hua Yin¹, Li-Xuan Sang², Bing Chang³

¹Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.

World journal of gastroenterology

|January 8, 2024

概括

非酒精性脂肪肝炎 (NASH) 的治疗方法有限. 像Semaglutide这样的葡萄糖类-1受体激动剂在NASH解决方面表现有前途,但在纤维化方面没有,因此需要对组合疗法的进一步研究.

科学领域:

肝病学肝病学是一种肝病学.
代谢疾病代谢疾病
药理学药理学是指药理学的学科.

背景情况:

非酒精性脂肪性肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH) 是肝病的重要原因,由代谢功能障碍驱动.
目前对NAFLD/NASH和相关的肝纤维化缺乏治疗选择.
胰岛素抵抗是NASH病变的一个关键因素,促使人们对糖尿病治疗的研究.

研究的目的:

评估类似葡萄糖类-1受体激动剂 (GLP-1RAs) 在治疗纳氏病时的疗效.
探索结合GLP-1RAs与NASH和肝纤维化抗纤维剂的潜力.
强调需要继续研究NAFLD/NASH的新型治疗策略.

主要方法:

对NAFLD/NASH患者的GLP-1RA塞马格卢提德现有研究的综述.
对研究GLP-1RA和抗纤维素药物的联合治疗的临床试验的分析.
评估这些疗法对NASH解决和肝纤维化的影响.

主要成果:

塞马格卢提德在解决纳氏血栓炎症方面表现出有效性,但没有改善肝纤维化.
涉及塞马格卢提德和抗纤维素药物的组合疗法表现出有限的成功,可能是由于试验持续时间很短.
GLP-1RAs代表了NASH的一个有前途的治疗途径.

结论:

改善肝纤维化对于NAFLD的长期预后至关重要.
针对NASH病理生理学的联合治疗方法需要进一步研究.
对GLP-1RAs和新型组合策略的持续关注对于推进NASH治疗至关重要.

关键词:

抗糖尿病药物抗糖尿病药物类似葡萄糖的1 类似葡萄糖的1 非酒精性脂肪性肝病是非酒精性脂肪性肝病.非酒精性脂肪肝炎的原因塞马格卢提德 (semaglutide) 是一种类型的

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Liver Physiology

Liver Physiology

The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...

cAMP-dependent Protein Kinase Pathways

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...